NCT07798505 A First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of HMB-003 in Healthy Volunteers
| NCT ID | NCT07798505 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Hemab ApS |
| Condition | Healthy Adult Participants |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-08-17 |
| Primary Completion | 2027-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 40 participants in total. It began in 2026-08-17 with a primary completion date of 2027-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purposes of this clinical study are 1. To see how the new drug (HMB-003) under study is tolerated in healthy volunteers, and if there are any important side effects. 2. To measure the amount of HMB-003 in the body after injection.
Eligibility Criteria
Inclusion Criteria: * Participant is aged 18 to 50 years, inclusive, at the time of signing informed consent. * Overall healthy as determined by medical evaluation including physical examination, vital signs, laboratory tests, and ECG. Exclusion Criteria: * Participant has a history of clinically significant hypersensitivity to any excipients of the study drug * Participant is pregnant, breastfeeding, or \<6 weeks postpartum. * Participant has received investigational drug or device in another clinical study within 30 days or 5 half-lives, whichever is longer, before dosing.
Contact & Investigator
Medical Director
STUDY DIRECTOR
Hemab
Frequently Asked Questions
Who can join the NCT07798505 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Healthy Adult Participants. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07798505 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07798505 currently recruiting?
Yes, NCT07798505 is actively recruiting participants. Contact the research team at clinicaltrials@hemab.com for enrollment information.
Where is the NCT07798505 trial being conducted?
This trial is being conducted at San Antonio, United States.
Who is sponsoring the NCT07798505 clinical trial?
NCT07798505 is sponsored by Hemab ApS. The principal investigator is Medical Director at Hemab. The trial plans to enroll 40 participants.